Lyons Ruth Anne 4
4 · ENDOLOGIX INC /DE/ · Filed Sep 11, 2012
Insider Transaction Report
Form 4
Lyons Ruth Anne
VP Global Marketing
Transactions
- Award
Common Stock
2012-09-09$12.62/sh+28,944$365,273→ 28,944 total
Footnotes (4)
- [F1]25% vesting to occur upon the achievement of Nellix device revenue target for a month.
- [F2]25% vesting to occur upon U.S. regulatory approval of Nellix device.
- [F3]25% vesting to occur upon U.S. regulatory approval of Ventana device.
- [F4]25% vesting to occur upon U.S.regulatory approval of a second-generation AFX device.